Comments: 0 | Likes: 0 | Current Price: ₹ 667.45
Syngene International Ltd.: Q2FY23 Result Update
About The Company
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
Q2FY23 Operating Highlights
Key Facts and Figure
Business Segments
Research Business
Discovery Services
Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody
drug conjugates, PROTACs
SynVent our proprietary platform for Integrated Drug Discovery
Dedicated R&D Centers
Ring-fenced infrastructure for exclusive operations for an individual client
Dedicated, multi-disciplinary team of scientists Access to entire Syngene ecosystem
for specialist research and development operations
Development and Manufacturing Business
Development Services
Pre-clinical to clinical trials
Drug substance and drug product development
Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate
cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules
Manufacturing Services
Manufacturing of small and large molecules for commercial supplies
cGMP-compliant facilities
State-of-the art API manufacturing and biologics manufacturing facilities
Capex Update
Financial Performance
Q2FY23 Financial Snapshot
I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Stocx Research Club). I have no business relationship with any company whose stock is mentioned in this article.
Source - Company's quarterly announcements, Concall and Presentation. Disc - Given company in the article is not for an recommendation.
I am not a SEBI Registered individual/entity and the above research article is only for educational purpose and is never intended as trading/investment advice.
Articles
Comments
